Aevi Genomic Medicine is a clinical stage biopharmaceutical company with a focus on identifying the genetic drivers of disease and applying this understanding to the pursuit of differentiated therapies for pediatric onset, life-altering diseases, including rare and orphan diseases. The company's product pipeline includes: AEVI-002, which is an anti-LIGHT monoclonal antibody that is in development for use in Pediatric Onset Crohn's disease; and AEVI-005, which is the monoclonal antibody the company is developing as part of its ongoing collaboration with Kyowa Hakko Kirin Co., Ltd. whereby the company is studying it in an undisclosed ultra-orphan auto-immune pediatric disease.
Zacks Investment Research is a Chicago based firm with over 30 years of experience in providing institutional and individual investors with the analytical tools and financial information necessary to the success of their investment process.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.